Bioavailability of alendronate and vitamin D3 in an alendronate/vitamin D3 combination tablet

Journal of Clinical Pharmacology

Volumn 51, Issue 10, 2011, Pages 1439-1448

  Denker, Andrew E ^a   Lazarus, Nicole ^a   Porras, Arturo ^a   Ramakrishnan, Rohini ^a   Constanzer, Marvin ^a   Scott, Boyd B ^a   Chavez Eng, Cynthia ^a   Woolf, Eric ^a   Maganti, Lata ^a   Larson, Patrick ^a   Gottesdiener, Keith ^a   Wagner, John A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Alendronate; bioavailability; bioequivalence; vitamin D

Indexed keywords

ALENDRONIC ACID; ALENDRONIC ACID PLUS COLECALCIFEROL; COLECALCIFEROL; HEMOGLOBIN;

ADULT; AGED; ARTICLE; BIOEQUIVALENCE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HUMAN; LEG PAIN; LOOSE FECES; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; SHOULDER PAIN; SIDE EFFECT; SINGLE DRUG DOSE; TABLET; THORAX PAIN;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALENDRONATE; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; BONE DENSITY CONSERVATION AGENTS; CHOLECALCIFEROL; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; TABLETS; YOUNG ADULT;

EID: 80053268801     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270010382010     Document Type: Article

References (33)

1. International Osteoporosis Foundation. Facts and statistics about osteoporosis and its impact. http://osteofound.org/press-centre/fact-sheet.html. Accessed March 17, 2010.
2. Johnell O, Kanis J. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006 ; 17: 1726-1733 (Pubitemid 44607392)
3. Rossini M, Bianchi G, Di Munno O, et al. Treatment of Osteoporosis in clinical Practice (TOP) Study Group. Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int. 2006 ; 17: 914-921 (Pubitemid 43781506)
4. McClung MR. Bisphosphonate in osteoporosis: recent clinical experience. Expert Opin Pharmacother. 2000 ; 1: 225-238
5. Rodan GA, Reszka AA. Bisphosphonate mechanism of action. Curr Mol Med. 2002 ; 2: 571-577 (Pubitemid 34982189)
6. Hirota K, Hirota T. Nutritional condition affect the potency of pharmacological therapy. Clin Calcium. 2005 ; 15: 1535-1539
7. Boonen S, Vanderschueren D, Haentjens P, Lips P. Calcium and vitamin D in the prevention and treatment of osteoporosis: a clinical update. J Intern Med. 2006 ; 259: 539-552
8. van den Berg H. Bioavailability of vitamin D. Eur J Clin Nutr. 1997 ; 51 (suppl 1). S76-S79
9. Holick MF. Vitamin D deficiency. N Engl J Med. 2007 ; 357: 266-281
10. Holick MF. High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc. 2006 ; 81: 353-373 (Pubitemid 43334631)
11. DeLuca HF. Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr. 2004 ; 80 (suppl). 1689S-1696S
12. Holick MF, Siris ES, Binkley N. Prevalence of vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy. J Clin Endocrinol Metab. 2005 ; 90: 3215-3224 (Pubitemid 41014278)
13. Heaney RP. Functional indices of vitamin D status and ramifications of vitamin D deficiency. Am J Clin Nutr. 2004 ; 80 (suppl). 1706S-1709S
14. Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E, Dietrich T, Dawson-Hughes B. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA. 2005 ; 293: 2257-2264 (Pubitemid 40629192)
15. Lips P, Duong T, Oleksik A, et al. A global study of vitamin D status and parathyroid function in postmenopausal women with osteoporosis: baseline data from the Multiple Outcomes of Raloxifene Evaluation clinical trial. J Clin Endocrinol Metab. 2001 ; 86: 1212-1221 (Pubitemid 32323007)
16. Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev. 2001 ; 22: 477-501 (Pubitemid 32762324)
17. Lips P, Binkley N, Pfeifer M, et al. High prevalence of vitamin D inadequacy among community dwelling post-menopausal women with osteoporosis. J Bone Miner Res. 2005 ; 20 (suppl 1). S378
18. Moniz C, Dew T, Dixon T. Prevalence of vitamin D inadequacy in osteoporotic hip fracture patients in London. Curr Med Res Opin. 2005 ; 21: 1891-1894 (Pubitemid 41803097)
19. Gallacher SJ, McQuillian C, Harkness M, Finlay F, Gallagher AP, Dixon T. Prevalence of vitamin D inadequacy in Scottish adults with non-vertebral fragility fractures. Curr Med Res Opin. 2005 ; 21: 1355-1361 (Pubitemid 41368566)
20. Gaugris S, Heaney RP, Boonen S, Kurth H, Bentkover JD, Sen SS. Vitamin D inadequacy among post-menopausal women: a systematic review. QJM. 2005 ; 98: 667-676 (Pubitemid 41236096)
21. Food and Agriculture Organization of the United Nations/World Health Organization. Human Vitamin and Mineral Requirements. 2002. http://www.fao.org/ docrep/004/y2809e/y2809e00.HTM
22. Uenishi K. Prevention of osteoporosis by foods and dietary supplements: prevention of osteoporosis by milk and dairy products. Clin Calcium. 2006 ; 16: 1606-1614
23. Weaver CM, Fleet JC. Vitamin D requirements: current and future. Am J Clin Nutr. 2004 ; 80 (suppl). 1735S-1739S
24. Holick MF. Vitamin D: a millennium perspective. J Cell Biochem. 2003 ; 88: 296-307
25. Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride. Washington, DC: National Academies Press ; 2005: 21-37.
26. European Medicines Agency. European Medicines Agency's public assessment report for Fosavance: scientific discussion. http://www.ema.europa.eu/humandocs/ Humans/EPAR/fosavance/fosavance.htm. Accessed March 17, 2010.
27. Recker R, Lips P, Felsenberg D, et al. Alendronate with and without cholecalciferol for osteoporosis: results of a 15-week randomized controlled trial. Curr Med Res Opin. 2006 ; 22: 1745-1755 (Pubitemid 44449231)
28. Binkley N, Novotny R, Krueger D, et al. Low vitamin D status despite abundant sun exposure. J Clin Endocrinol Metab. 2007 ; 92: 2130-2135 (Pubitemid 46997111)
29. World Medical Association. Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. http://www.wma.net/en/ 30publications/10policies/b3/index.html. Accessed March 17, 2010.
30. Chen TC, Turner AK, Holick MF. A method for the determination of the circulating concentration of 1,25-dihydroxyvitamin D. J Nutr Biochem. 1990 ; 1: 320-327 (Pubitemid 20246337)
31. Porras AG, Holland SD, Gertz BJ. Pharmacokinetics of alendronate. Clin Pharmocokinet. 1999 ; 36: 315-328 (Pubitemid 29261508)
32. Gertz BJ, Holland SD, Kline WF, et al. Studies of the oral bioavailability of alendronate. Clin Pharmacol Ther. 1995 ; 58: 288-298
33. Whitehouse Station, NJ: Merck & Co ; 2010 :